G1 Therapeutics, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021
August 04, 2021 at 04:01 pm EDT
Share
G1 Therapeutics, Inc. announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced total revenue was USD 6.604 million compared to USD 2.140 million a year ago. Operating loss was USD 38.192 million compared to USD 30.822 million a year ago. Net loss was USD 39.422 million compared to USD 31.210 million a year ago. Basic loss per share from continuing operations was USD 0.94 compared to USD 0.83 a year ago. For the half year, total revenue was USD 20.822 million compared to USD 2.140 million a year ago. Operating loss was USD 63.727 million compared to USD 62.643 million a year ago. Net loss was USD 65.864 million compared to USD 62.233 million a year ago. Basic loss per share from continuing operations was USD 1.59 compared to USD 1.65 a year ago.
G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of small molecule therapeutics for the treatment of patients with cancer. The Company's lead commercial product, COSELA (trilaciclib), is a therapy indicated to proactively help protect bone marrow (myeloprotection) from the damage of chemotherapy. Its product portfolio consists of Trilaciclib and Lerociclib, both of which are CDK4/6 inhibitors, and a Cyclin-dependent kinase 2 (CDK2) inhibitor. Trilaciclib is a novel therapy designed to transiently arrest cells that are dependent on CDK4/6 for proliferation, including hematopoietic stem and progenitor cells (HSPCs), in the G1 phase. Lerociclib is a differentiated clinical-stage oral CDK4/6 inhibitor being developed for use in combination with other targeted therapies in multiple oncology indications. COSELA is a short-acting intravenous CDK4/6 inhibitor. Its CDK2 is an internally discovered inhibitor.
G1 THERAPEUTICS, INC. 
